Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

How Your Patients' Non-REM Sleep Changes On Sedatives in the Intensive Care Units (HYPNOS)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Paula Watson, Vanderbilt University Identifier:
First received: January 20, 2009
Last updated: November 4, 2015
Last verified: November 2015
The purpose of this study is to study the effect of two standard of care sedative medications on sleep stages and total sleep time. The investigators hypothesize that the α2 agonist, dexmedetomidine, will improve sleep quality by increasing N2 and N3 sleep as well as total sleep time when compared to GABA agonists.

Condition Intervention
Respiratory Failure
Drug: Dexmedetomidine
Drug: GABA agonist

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Official Title: Comparison of Polysomnographic Findings in Mechanically Ventilated Patients Sedated With α2 Agonists Versus GABA Agonists

Further study details as provided by Vanderbilt University:

Primary Outcome Measures:
  • Time spent in standard sleep stages (N1, N2, N3, REM). [ Time Frame: 4 days ]

Secondary Outcome Measures:
  • Time spent in atypical sleep. [ Time Frame: 4 days ]
  • Presence of burst suppression. [ Time Frame: 4 days ]

Estimated Enrollment: 30
Study Start Date: January 2009
Estimated Study Completion Date: December 2016
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GABA agonist Drug: GABA agonist
Patients sedated with GABA agonists (e.g. propofol, benzodiazepines) during mechanical ventilation will be enrolled. Patients randomized to the GABA agonist arm will continue the sedative that is active at enrollment. The specific drug as well as dosage, frequency, and duration will be determined and titrated by the managing clinical team.
Other Names:
  • Typical GABA agonists include:
  • 1) propofol
  • 2) midazolam
  • 3) lorazepam.
Experimental: Alpha 2 agonist Drug: Dexmedetomidine
Standard of care sedative. Dosage, frequency, and duration will be determined by the managing clinical team.

Detailed Description:
This is a single center randomized pilot study comparing the effects of an α2 agonist (dexmedetomidine) versus GABA agonists (propofol or a benzodiazepine) on total sleep time and sleep quality. For the purposes of enrollment and analysis all benzodiazepines used for sedation (mainly midazolam and lorazepam) will be considered equivalent. Patients who are mechanically ventilated and sedated will be enrolled. The initial sedative will be determined by the managing medical team and the medication will be active at the time of enrollment. The patients will then be randomized to either continue their current sedative or be switched to either propofol or dexmedetomidine. PSG data will be collected for up to 96 hours, beginning at enrollment for all patients. The analysis of PSG will not begin until after a 8 hour "washout" period has completed to minimize carryover effect of prior sedatives.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult patients admitted to the medical intensive care unit who require mechanical ventilation and are sedated with a GABA agonist with the expectation of being mechanically ventilated for greater than 24 hours.

Exclusion Criteria:

  • Subjects who are less than 18 years
  • Subjects who are pregnant (a pregnancy test will be performed on all women of child bearing age)
  • Inability to obtain informed consent from the patient or his/her surrogate
  • Subjects who are physiologically benzodiazepine dependent, and at risk of withdrawal syndromes
  • Subjects with anoxic brain injuries, strokes, or neurotrauma
  • Medical team following patient unwilling to change sedation regimen
  • Subjects who are moribund and not expected to survive 24 hours or actively withdrawing medical support
  • Documented allergy to study medications
  • Subjects with advanced heart block at time of screening
  • Prisoners
  • RASS target of less than or equal to -4 at the time of screening
  • PSG equipment unavailable
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00826553

United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Vanderbilt University
Principal Investigator: Paula L Watson, MD Vanderbilt School of Medicine
  More Information

Responsible Party: Paula Watson, Assistant Professor of Medicine, Vanderbilt University Identifier: NCT00826553     History of Changes
Other Study ID Numbers: 081170
Study First Received: January 20, 2009
Last Updated: November 4, 2015

Keywords provided by Vanderbilt University:
alpha 2 agonist

Additional relevant MeSH terms:
Respiratory Insufficiency
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Neurocognitive Disorders
Mental Disorders
Respiration Disorders
Respiratory Tract Diseases
Hypnotics and Sedatives
gamma-Aminobutyric Acid
GABA Agonists
Central Nervous System Depressants
Physiological Effects of Drugs
Anesthetics, Intravenous
Anesthetics, General
Adjuvants, Anesthesia
Anti-Anxiety Agents
Tranquilizing Agents
Psychotropic Drugs
GABA Modulators
GABA Agents
Neurotransmitter Agents processed this record on April 26, 2017